Primary Myelofibrosis (PMF)

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Extended Access of Momelotinib in Adults With Myelofibrosis

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis

Managed Access Programs for INC424, Ruxolitinib

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)